Intensive Intravesical BCG-induction in Patients with Asymptomatic Bacteriuria Asymptomatic bacteriuria (ABU) is common in adults with bladder cancer and does not require routine antibacterial therapy.1 Intravesical BCG is standard of care for high-risk non-muscle-invasive bladder cancer. We showed that BCG therapy is safe to administer in patients with ABU,2 and early responses were similar, and in some cases superior, to those in uninfected patients.3,4 This study evaluates the safety and efficacy of BCG in patients with ABU enrolled in a prospective study to receive sequential double-induction intravesical BCG treatments.
https://www.goldjournal.net/ar....ticle/S0090-4295(25)

Detection Of High-Grade Bladder Cancer In Urine Samples Using In Situ Hybridization Of Long Non-Coding RNA UCA1 To evaluate the performance of urinary biomarker long non-coding RNA urothelial carcinoma-associated 1 (UCA1) in detection of high-grade bladder cancer (BCa) using RNA in situ hybridization (RISH). Urine cytology and cystoscopy are the gold standard for BCa detection. There is a paucity of reliable urinary biomarkers for BCa detection in clinical practice.
https://www.goldjournal.net/ar....ticle/S0090-4295(25)

Long-term Outcomes of Conservative Management for Lichen Sclerosus Urethral Stricture Disease To examine the long-term outcomes of conservative management of lichen sclerosus-induced urethral stricture disease (LS-USD).
https://www.goldjournal.net/ar....ticle/S0090-4295(25)

Demographics, Complications, and Management of Genitourinary Gunshot Wounds: National Trauma Data Bank Analysis To evaluate the national prevalence and in-hospital outcomes of genitourinary-related (kidney, ureteral, bladder, urethral, penile, genital) gunshot wounds.
https://www.goldjournal.net/ar....ticle/S0090-4295(25)

Should We Incorporate Urinary Tumour DNA Status in Treatment Decisions for Patients with Non–muscle-invasive Bladder Cancer? In this issue of European Urology, St-Laurent et al [1] report that detectable levels of urinary tumour DNA (utDNA) are highly predictive of recurrence in patients with bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) treated with atezolizumab in SWOG S1605, a single-arm phase 2 trial. Just as the presence of detectable circulating tumour DNA (ctDNA) before, during, or after treatment for patients with muscle-invasive bladder cancer (MIBC) has important prognostic implications [2], detection of utDNA before, during, or after treatment of NMIBC may also be prognostic.
https://www.europeanurology.co....m/article/S0302-2838